|
gptkbp:instanceOf
|
gptkb:drug
benzodiazepine
|
|
gptkbp:ATCCode
|
N05BA09
|
|
gptkbp:bioavailability
|
87% (oral)
|
|
gptkbp:brand
|
Frisium
Onfi
Urbanol
|
|
gptkbp:broadcastOn
|
Schedule IV (US)
|
|
gptkbp:CASNumber
|
22316-47-8
|
|
gptkbp:contraindication
|
gptkb:myasthenia_gravis
severe respiratory insufficiency
|
|
gptkbp:discoveredBy
|
gptkb:Hoechst
|
|
gptkbp:eliminationHalfLife
|
10-50 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:hasMolecularFormula
|
C16H13ClN2O2
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Clobazam
|
|
gptkbp:interactsWith
|
gptkb:beer
opioids
other CNS depressants
|
|
gptkbp:introducedIn
|
1975
|
|
gptkbp:IUPACName
|
7-chloro-1-methyl-5-phenyl-1,5-benzodiazepine-2,4-dione
|
|
gptkbp:KEGGID
|
gptkb:D07714
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
positive allosteric modulator of GABAA receptor
|
|
gptkbp:MedlinePlusID
|
a682059
|
|
gptkbp:metabolism
|
liver
N-desmethylclobazam
|
|
gptkbp:overdoseSymptoms
|
confusion
coma
respiratory depression
somnolence
|
|
gptkbp:pregnancyCategory
|
gptkb:D_(Australia)
C (US)
|
|
gptkbp:pregnancyRisk
|
may cause fetal harm
|
|
gptkbp:proteinBinding
|
80-90%
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL656
2699
2802
DB00349
|
|
gptkbp:riskOfDependence
|
yes
|
|
gptkbp:riskOfWithdrawal
|
yes
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
constipation
fatigue
aggression
drowsiness
respiratory depression
|
|
gptkbp:UNII
|
5C481Y6L9Q
|
|
gptkbp:usedFor
|
gptkb:Lennox-Gastaut_syndrome
epilepsy
anxiety disorders
|
|
gptkbp:bfsParent
|
gptkb:Schedule_IV_controlled_substances
gptkb:N05BA
|
|
gptkbp:bfsLayer
|
7
|